Dr. Louis Peter Fuerstman, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 196 Ridgecrest Cir, Clayton, GA 30525 Phone: 706-782-4233 |
Dr. Michael Hollifield, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 563 Mountain City Rd, Clayton, GA 30525 Phone: 706-960-9533 Fax: 706-782-0465 |
News Archive
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
A new study has found that one in every six persons diagnosed with HIV is over the age of 50 years. This new study was published yesterday (26th September 2017) in the journal Lancet HIV.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for the proprietary Urgent PC device was effective August 10, 2014.
In the scientific article recently published in Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, Erica Ramstad and others reviewed the existing evidence between various psychotic symptoms such as hallucinations, problems with concentration or anxiety with methylphenidate, a drug commonly prescribed as a treatment for attention deficit hyperactivity disorder and narcolepsy.
Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).
› Verified 9 days ago